Immunotherapy for advanced renal cell cancer.
By C. Coppin, F. Porzsolt, M. Autenrieth, Julia Kumpf, A. Coldman, T. Wilt. Cochrane Database of Systematic Reviews, 2015
619 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/5c279a6e3e137d00ea0270b738ea0e7fdaac41d1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- EAU guidelines on renal cell carcinoma: the 2010 update. (2010, background): “IFN-a provided a response rate of 6–15% and a modest survival benefit of 3–5 mo [41].”
- EAU guidelines on renal cell carcinoma: 2014 update. (2010, neutral): “IFN-a provided a response rate of 6–15% and a modest survival benefit of 3–5 mo [41].”
- Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. (2010, background): “IFN- has also demonstrated a modest overall survival (OS) advantage over hormones and chemotherapy in randomized trials and a meta-analysis.(1,2,4) The addition of interleukin-2, hormones, or antiproliferative agents such as cis-retinoic acid has not demonstrated significant advantages over IFNmonot”